Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.109050410.3389/fphar.2022.1090504PharmacologyEditorialEditorial: New compounds, novel targets and mechanism study in inflammation-associated liver diseasesWu10.3389/fphar.2022.1090504WuBaoming*School of Pharmacy, Anhui Medical University, Hefei, China
Edited and reviewed by:Angelo A. Izzo, University of Naples Federico II, Italy
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Editorial on the Research Topic New compounds, novel targets and mechanism study in inflammation-associated liver diseasesliver diseasesimmune cellsimmunoregulationnovel targetsdrug discovery
This Research Topic was initiated to investigate the pathogenesis and pathophysiological processes of inflammation-associated liver diseases, with particular focus on targets research, drug conversion, and druggability research, based on the informatics approach and further discovery of novel therapeutic targets and strategies for treatment.
Total of 18 manuscripts were submitted and reviewed, with 9 manuscripts accepted and others rejected. Scopes of accepted manuscripts involved liver injury, autoimmune hepatitis, liver ischemia/reperfusion injury and liver fibrosis. There were 3 manuscripts that discussed effects of Chinese traditional medicine on liver diseases: paeoniflorin alleviates liver injury in hypercholesterolemic rats through the ROCK/AMPK pathway (Liu et al.), mechanism of Hydroxysafflor yellow A on acute liver injury based on transcriptomics (Hou et al.), and saikosaponin d alleviates liver fibrosis by negatively regulating the ROS/NLRP3 inflammasome through activating the ERβ pathway (Zhang et al.). There were 2 manuscripts that studied the effects and mechanism of chemical medicine on liver diseases: hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes (Jiu et al.), and roxadustat, a hypoxia-inducible factor 1α activator, attenuates both long-and short-term alcohol induced alcoholic liver disease (Gao et al.). There were 3 manuscripts that revealed the effects and mechanism of cytokines on liver diseases: inhibition of macrophage migration inhibitory factor (MIF) suppresses apoptosis signal-regulating kinase 1 to protect against liver ischemia/reperfusion injury (Chen et al.), human umbilical cord blood mononuclear cells ameliorate CCl4 induced acute liver injury in mice via inhibiting inflammatory responses and up-regulating interleukin-22 (Zhang et al.), and interleukin-6 receptor blockade can increase the risk of nonalcoholic fatty liver disease: indications from Mendelian randomization (Li et al.). There was 1 review manuscript in this Research Topic, which summarized the current literature regarding FAT10 role in developing liver diseases and potential therapeutic targets for nonalcoholic/alcoholic fatty liver disease and hepatocellular carcinoma (Wimalarathne et al.).
Author contributions
The author confirms being the sole contributor of this work and has approved it for publication.
In the end, I would like to first thank our guest editors (Dr. Lei Zhang, Dr. Yang Yang, Dr. Xiude Fan, and Dr. Tatsunori Miyata), because they worked very hard to organize the Research Topic and review manuscripts assigned to them. Second, I would like to thank all the contributors who submitted their great work to this topic. Last but not the least, we would like to thank Frontier in Pharmacology for giving us this opportunity to learn a great deal from this special issue.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesMadushikaM.Wilkerson-VidalQ. C.HuntE. C.Love-RutledgeS. T. (2022). The case for FAT10 as a novel target in fatty liver diseases. Front. Pharmacol.13, 972320. 10.3389/fphar.2022.972320TongL.ZhangN.KongL.ChuS.ZhangT.YanG. (2022). Paeoniflorin alleviates liver injury in hypercholesterolemic rats through the ROCK/AMPK pathway. Front. Pharmacol.13, 968717. 10.3389/fphar.2022.968717